Long Term Follow-up on Menkes Disease Patients

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Menkes Disease
Interventions
DRUG

Long Term Follow-Up

"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."

Trial Locations (1)

10014

Cyprium Study Team, New York

Sponsors
All Listed Sponsors
lead

Cyprium Therapeutics, Inc.

INDUSTRY